Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance. (Q54361471)

28 May 2018

title

Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance. (English)

1 reference

28 May 2018

0 references

1 reference

Pauline Wimberger

1

1 reference

28 May 2018

Issam Chebouti

2

1 reference

28 May 2018

Sabine Kasimir-Bauer

3

1 reference

28 May 2018

Robert Lachmann

4

1 reference

28 May 2018

Eberhard Kuhlisch

5

1 reference

28 May 2018

Rainer Kimmig

6

1 reference

28 May 2018

Ergün Süleyman

7

1 reference

28 May 2018

Jan Dominik Kuhlmann

8

1 reference

28 May 2018

language of work or name

English

0 references

publication date

5 April 2014

1 reference

28 May 2018

published in

Gynecologic Oncology

1 reference

28 May 2018

volume

133

1 reference

28 May 2018

page(s)

467-472

1 reference

28 May 2018

issue

3

1 reference

28 May 2018

Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Management of recurrent ovarian carcinoma: current status and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

VEGF and the quest for tumour angiogenesis factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Biomarkers in the development of anti-angiogenic therapies for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

VEGF-targeted therapy: mechanisms of anti-tumour activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

A phase 3 trial of bevacizumab in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Incorporation of bevacizumab in the primary treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Vascular endothelial growth factor expression in early stage ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Zone-specific remodeling of tumor blood vessels affects tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

VEGF-A165 induces human aortic smooth muscle cell migration by activating neuropilin-1-VEGFR1-PI3K axis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Functional significance of VEGFR-2 on ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

The role of the tumor microenvironment in regulating angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Biomarkers of response and resistance to antiangiogenic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

10.1016/J.YGYNO.2014.03.574

7 January 2021

Identifiers

DOI

1 reference

28 May 2018

PubMed ID

24713547

1 reference

28 May 2018